📰 Nasdaq Algs News
Nasdaq Algs News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Algs. Real-time updates on events, politics, business and more.
February 17, 2024
Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 894,500 shares, a growth of 6.4% from the January 15th total of 840,400 shares. Based on an average daily volume of 294,500 shares, […]
January 27, 2024
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) and INmune Bio (NASDAQ:INMB – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings. Risk and Volatility Aligos Therapeutics has a […]
January 27, 2024
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) and INmune Bio (NASDAQ:INMB – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability. Volatility and Risk Aligos Therapeutics has a […]
September 7, 2023
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) and LadRx (OTCMKTS:CYTR – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation. Risk and Volatility Aligos Therapeutics has a beta […]
May 12, 2023
Aligos Therapeutics (NASDAQ:ALGS – Get Rating) and Vigil Neuroscience (NASDAQ:VIGL – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability. Profitability This table compares Aligos Therapeutics and Vigil Neuroscience’s […]
May 9, 2023
Aligos Therapeutics (NASDAQ:ALGS – Get Rating) and Caribou Biosciences (NASDAQ:CRBU – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership. Profitability This table compares Aligos Therapeutics and Caribou Biosciences’ […]
April 28, 2023
Aligos Therapeutics (NASDAQ:ALGS – Get Rating) is scheduled to be releasing its earnings data after the market closes on Thursday, May 4th. Analysts expect Aligos Therapeutics to post earnings of ($0.47) per share for the quarter. Aligos Therapeutics (NASDAQ:ALGS – Get Rating) last issued its quarterly earnings results on Thursday, March 9th. The company reported […]
April 11, 2023
SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...
September 28, 2022
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...
May 25, 2022
Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Rating) has received an average rating of “Hold” from the six analysts that are covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year price objective among brokerages that […]